pre-IPO PHARMA

Slayback Pharma announces approval of Icatibant Injection 30 mg/3 ml (10 mg/ ml), generic equivalent of Firazyr.

Tags:  


PRINCETON, N.J., Sept. 2, 2020 /PRNewswire/ -- Slayback Pharma, LLC announced today that it has received final approval for its ANDA for Icatibant Injection 30 mg/3 ml (10 mg/ml) in a Prefilled Syringe - a generic equivalent of Firazyr®.


Ajay Singh, CEO of Slayback Pharma, said: “We are pleased to announce the approval of our ANDA for Icatibant - another complex generic injectable of a difficult-to-characterize peptide and a drug-device combination. We are particularly excited at the opportunity to enhance the affordability of yet another expensive orphan drug.”



See the following important safety information and refer to the package insert for full prescribing information.


Indication

Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.


Important Safety Information for Icatibant

Angioedema (which can include swelling of the throat or larynx) can be life-threatening.  Inject Icatibant and go to the nearest hospital emergency room immediately if you have a laryngeal attack.


These are not all the possible side effects of Icatibant. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.


 

Tell your healthcare provider if you have any other medical conditions.  You and your healthcare provider will decide if Icatibant is right for you.



For more information, please see full Prescribing Information.


You are encouraged to report any side effects or adverse event by calling 1-844-566-2505 or emailing [email protected].  If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly at fda.gov/medwatch or call 1-800-FDA-1088.


Slayback Pharma is a New Jersey-based pharmaceutical company focused on the development of complex and specialty generic products.


Intended only for residents of the United States of America. © 2020 Slayback Pharma, Princeton, NJ  08540


References: Icatibant Injection prescribing information. Slayback Pharma, 6/2020 Firazyr® is a registered trademark of Shire, a Takeda company.  



SOURCE Slayback Pharma LLC

http://www.slayback-pharma.com

More news releases in similar topics

888-776-0942 from 8 AM - 9 PM ET